Literature DB >> 18024893

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.

Christine Meisinger-Henschel1, Michaela Schmidt, Susanne Lukassen, Burkhard Linke, Lutz Krause, Sebastian Konietzny, Alexander Goesmann, Paul Howley, Paul Chaplin, Mark Suter, Jürgen Hausmann.   

Abstract

Chorioallantois vaccinia virus Ankara (CVA) is the parental virus of modified vaccinia virus Ankara (MVA), which was derived from CVA by more than 570 passages in chicken embryo fibroblasts (CEF). MVA became severely host-cell-restricted to avian cells and has strongly diminished virulence in mammalian hosts, while maintaining good immunogenicity. We determined the complete coding sequence of the parental CVA and mapped the exact positions of the six major deletions that emerged in the MVA genome. All six major deletions occurred in regions of the CVA genome where one or more truncated or fragmented open reading frames (ORFs) pre-existed. The CVA genome contains 229 ORFs of which 51 are fragments of full-length orthopoxvirus (OPV) genes, including fragmented orthologues of C9L and M1L (encoding two well-conserved ankyrin-like proteins), A39R (encoding a semaphorin-like protein) and A55R (encoding a kelch-like protein). Phylogenetic analysis demonstrated that MVA was most closely related to CVA, followed by the vaccinia virus (VACV) strain DUKE, a patient-derived isolate of the Dryvax vaccine virus. Loss or mutation of genes outside the six major deletions are assumed to contribute to the restricted host range phenotype of MVA. In support of this notion, deletions, insertions and non-synonymous mutations were found in 122 of the 195 ORFs remaining in MVA when compared with their CVA counterparts. Thus, detailed knowledge of the CVA genomic sequence is a prerequisite to further dissect the genetic basis of the MVA host range phenotype as well as the particular immunological properties of MVA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024893     DOI: 10.1099/vir.0.83156-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  50 in total

1.  Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus.

Authors:  Tatiana G Senkevich; Erik K Zhivkoplias; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

2.  Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.

Authors:  Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

3.  Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Authors:  Gary Hermanson; Sookhee Chun; Jiin Felgner; Xiaolin Tan; Jozelyn Pablo; Rie Nakajima-Sasaki; Douglas M Molina; Philip L Felgner; Xiaowu Liang; D Huw Davies
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

4.  Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Authors:  Marc Schweneker; Andrea S Laimbacher; Gert Zimmer; Susanne Wagner; Elisabeth M Schraner; Michael Wolferstätter; Marieken Klingenberg; Ulrike Dirmeier; Robin Steigerwald; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

5.  Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response.

Authors:  Karen Buttigieg; Stephen M Laidlaw; Craig Ross; Marc Davies; Stephen Goodbourn; Michael A Skinner
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

6.  Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Authors:  Nicole L Garza; Josh M Hatkin; Virginia Livingston; Donald K Nichols; Paul J Chaplin; Ariane Volkmann; Diana Fisher; Aysegul Nalca
Journal:  Vaccine       Date:  2009-07-24       Impact factor: 4.169

7.  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Authors:  Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

8.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

9.  Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain.

Authors:  Mónica Morales; Miguel A Ramírez; María J Cano; Mario Párraga; Joaquín Castilla; Luis I Pérez-Ordoyo; Juan M Torres; Juan Bárcena
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

10.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.